{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-034907","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.715949+00:00","generated_at":"2026-05-15T08:50:20.078535+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MetaVia reports FY2025 net loss $13.0M; DA-1726 Phase 1 shows 9.1% weight loss","bullets":["Net loss of $13.0M ($7.35/share) vs $27.6M ($39.13/share) in FY2024; revenue not reported.","Cash and cash equivalents $10.3M at Dec 31, 2025; with Jan 2026 $9.3M offering, funds operations into Q4 2026.","DA-1726 48 mg Phase 1 data: 9.1% weight loss, reduced waist circumference, improved glucose and liver stiffness.","Phase 1 Part 3 titration study (48 mg and 64 mg) IRB approved; dosing starts April 2026, data expected Q4 2026.","Vanoglipel Phase 2a MASH data presented at AASLD; end-of-Phase 2 FDA meeting being scheduled."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-034907","json":"https://secwatch.observer/filing/0001104659-26-034907.json","markdown":"https://secwatch.observer/filing/0001104659-26-034907.md","text":"https://secwatch.observer/filing/0001104659-26-034907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/0001104659-26-034907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/mtva-20260326x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:50:20.078535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5547ddee08d5527f44df1be6549c1562738bf189","claim":"MetaVia Inc. reported financial results for the year ended December 31, 2025.","evidence_excerpt":"On March 26, 2026, MetaVia Inc. issued a press release announcing its financial results for the year ended December 31, 2025 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/0001104659-26-034907-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}